Amgen study met its primary endpoint after stock ends session up 2%

Traders Union
All News
Business & Wealth
Companies
Amgen stock rises 2% to $393.64

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

22.09.2026

Amgen study met its primary endpoint after stock ends session up 2% — Amgen stock rises 2% to $393.64

Amgen announced that a Phase 3 study of its investigational therapy for patients with moderate-to-severe Sjogren’s disease activity reached its primary endpoint on September 7, 2026. Separately, shares are up 2% at $393.64.

AMGN price prediction

24H 0.03%

$417.68

48H -0.03%

$417.46

7D 0.37%

$419.11

1M 6.28%

$443.79

3M 20.19%

$501.88

6M 37.36%

$573.57

12M 56%

$651.42

Current price: $417.57 2.67 0.64%

Closed 10/12

Daily range 413.61

417.73

Weekly range 396.21

417.78

Loading...

Highlights

Amgen reported that its Phase 3 investigational therapy for moderate-to-severe systemic Sjogren's disease met its primary endpoint.
Shares of Amgen are up 2% at $393.64, with the company valued near $212.56 billion and trailing revenue of $38.09 billion.
54 of 136 analysts rate Amgen stock a buy and HSBC most recently set a $425 price target with a hold rating.

Amgen announced on September 7, 2026 that its Phase 3 study of an investigational therapy for moderate-to-severe systemic Sjogren's disease activity achieved its primary endpoint. The information was shared through the company's official account.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Bullish structure holds as price challenges weekly resistance

Price is testing resistance from the weekly high at $394.45, challenging a level that has capped advances recently. Shares of Amgen are navigating a split daily structure, sitting below the MA-20 and MA-50 but holding above the MA-200. The recent trend has been firmly higher over the past week, and the daily move aligns with the broader bullish chart structure.

Odds favor upside as traders focus on the $394.45 close

Traders should watch for a close above $394.45 to gauge whether buyers are gaining control. The price is probing resistance from the weekly high without breaking through that level. Even so, from here the probability of further upside is 57% and the probability of downside is 43% over the next five trading days, with an expected range from $384.77 to $402.5. A strong close above $394.45 would show buyers are willing to follow through, while a drop below $374.63 would indicate the recent move is being faded. On the weekly chart the longer-term picture stays constructive.

Previously it was reported that Amgen shares faced downside risk following a key clinical milestone in small cell lung cancer, with technical signals indicating ongoing selling pressure. The latest Phase 3 success in Sjogren’s disease adds a new catalyst, and traders should now monitor price action around the $394.45 resistance to gauge whether a sustained breakout or renewed pullback emerges.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Tokens without buyers: Why NFT marketplaces are shutting down

By Mikhail Vnuchkov
1 hour ago

Tokens without buyers: Why NFT marketplaces are shutting down

Editors' Picks

Is it bad to be rich: Why billionaires are seen as villains

By Alena Volkova
4 hours ago

Is it bad to be rich: Why billionaires are seen as villains

Editors' Picks

What is a national blockchain network and does the world need one?

By Olena Litvinenko
Yesterday

What is a national blockchain network and does the world need one?

Editors' Picks

All Editors' Top Picks

Latest Amgen News

Amgen stock breakout attempt: Upside targets to watch

By Viktoras Karapetjanc
22.09.2026

Amgen stock breakout attempt: Upside targets to watch

Stocks

#Forecast #Amgen

AMGN slides as selloff dominates the short-term trend

By Andrey Mastykin
08.09.2026

AMGN slides as selloff dominates the short-term trend

Stocks

#Forecast #Amgen

Amgen announces Phase 3 DLL3-therapy study met primary endpoint as stock falls 7.5%

By Mykhailo Ihnatenko
08.09.2026

Amgen announces Phase 3 DLL3-therapy study met primary endpoint as stock falls 7.5%

Companies

Mikhail Vnuchkov
1 hour ago

Tokens without buyers: Why NFT marketplaces are shutting down

Alena Volkova
4 hours ago

Is it bad to be rich: Why billionaires are seen as villains

Olena Litvinenko
Yesterday

What is a national blockchain network and does the world need one?

Eugene Komchuk
Yesterday

CertiK expert: Hackers are winning the arms race for now

Dmytro Kharkov
Yesterday

Ledger’s spy chip scandal: Can hardware wallets still guard crypto’s cold storage?

Igor Krasulya
3 min ago

Stop showcasing trading profits online, Jameson Lopp advises

Yaroslav Dmytrenko
3 min ago

Tom McClellan: Yield curve shift now favors small caps

Oksana Koneva
8 min ago

Yi He: Binance AI fully rolled out and open for user feedback

Mykhailo Ihnatenko
8 min ago

Ivan Liljeqvist: Ledger owners warned about fake urgent emails amid supply chain hack concerns

Hanna Syniavska
8 min ago

Crypto market endures massive leverage loss, Ran Neuner notes

Top News

Igor Krasulya
1 hour ago

Cathie Wood warns of risks in memory chip stocks

Cathie Wood warns of risks in memory chip stocks

Olga Shendetskaya
5 hours ago

Gold prices rise as Middle East tensions complicate Fed rate outlook

Gold prices rise as Middle East tensions complicate Fed rate outlook

Olga Shendetskaya
5 hours ago

Asian tech shares fall sharply as doubts grow over AI profits

Asian tech shares fall sharply as doubts grow over AI profits

Eugene Komchuk
6 hours ago

Bitcoin falls below $82,000 before recovering

Bitcoin falls below $82,000 before recovering

Andrey Mastykin
21 hours ago

Oil prices hit near two-week highs as Houthi strikes threaten Gulf shipping

Oil prices hit near two-week highs as Houthi strikes threaten Gulf shipping

Top 5 companies for you

United States

Live News

Mykhailo Ihnatenko
Now

Nvidia stock tests key support as China competition intensifies

Ivan Andriyenko
Now

U.S. stock futures mixed as chip stocks extend losses

Anton Kharitonov
Now

EUR/USD remains under pressure as dollar strength and European risks weigh on the euro

Ivan Andriyenko
Now

Plus500 acquires Hedge Capital Markets to expand U.S. trading business

Eugene Komchuk
Now

Robbers steal nearly $800,000 from crypto trader in the UK

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.